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60 The Journal of Thoracic and CardiovObjective: Airway bypass by transbronchial fenestration has been shown to improve
forced expiratory volume and flow in explanted emphysematous human lungs. We
previously demonstrated the feasibility and safety of airway bypass stent placement
in a canine model, but we found that most stents occluded within 1 week. The aim
of this study was to evaluate the influence of controlled-release paclitaxel-eluting
stents on prolongation of patency.
Methods: With the subject dogs under general anesthesia, suitable segmental and
subsegmental bronchial wall sites were selected by direct visualization with a
flexible bronchoscope. A Doppler probe was used to detect and avoid sites with
adjacent blood vessels. Transbronchial passages were formed with a 25-gauge
transbronchial needle-tipped catheter and dilated with a 2.5-mm balloon integrated
into the needle catheter. A specifically designed expandable stainless steel stent (3
mm long  3 mm wide) embedded in a sleeve of silicone rubber was placed within
the passage and expanded until secured about the bronchial wall. Fifty control stents
(no paclitaxel impregnation) and 107 paclitaxel-eluting stents were placed in 25
dogs. Animals underwent bronchoscopy at intervals to assess stent patency.
Results: Eight instances of minor and brief bleeding occurred during stent placement;
all resolved without incident. There were no pneumothoraces or deaths associated with
stent placement. No delayed complications occurred. No identifiable paclitaxel-related
toxicity was observed. At 1, 4, 8, and 12 weeks, the patency rates were 10%, 0%, 0%,
and 0% for control stents and 100%, 96%, 76%, and 65% for paclitaxel stents.
Conclusion: In an animal model, the use of specifically designed paclitaxel-eluting
airway bypass stents was both feasible and safe. These stents resulted in a significant
prolongation of patency.
Collateral ventilation, the ability of gas to move from one part of the lung toanother through nonanatomic pathways, was first observed by Van Allenand colleagues1 in 1930. The importance of collateral ventilation is minimal
in normal lungs, because the resistance to air flow is higher in collateral channels
than in the airway.2 However, the resistance of air flow in collateral channels is low
in patients with emphysema relative to that in normal lungs.2,3 In emphysematous
lungs, collateral ventilation provides important channels for gas distribution and
may be therapeutically useful.4 We have previously demonstrated that creation of
direct passages between emphysematous pulmonary parenchyma and bronchial
airways (airway bypass) in excised emphysematous human lungs can improve
expiratory flow and volume, which is otherwise limited by the collapse of the small,
peripheral airways during expiration.5 Our ex vivo study of 12 emphysematous
human lungs demonstrated that creation of three passages improved mean forced
expiratory volume in 1 second from 245 mL to 447 mL. The addition of two more
passages further improved mean forced expiratory volume in 1 second to 666 mL.
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sages can be safely created in patients with emphysema.6 In
a separate animal study, we showed that it was feasible and
safe to place airway bypass stents in vivo.7 Most of the
stents, however, became occluded within 1 week after
placement, and this would pose a major problem for poten-
tial clinical application.7 The topical application of mitomy-
cin, an anti-inflammatory and antifibrotic agent, has been
reported to be useful in the treatment of airway stenosis.8,9
We evaluated the influence of weekly topical mitomycin on
airway bypass stent patency and found it to prolong stent
patency.7 The duration of stent patency was associated with
the number of weekly topical mitomycin applications. How-
ever, it is not practical to subject patients to weekly bron-
choscopic topical application of mitomycin to prolong stent
patency. The aim of this study was therefore to evaluate the
influence of controlled-release paclitaxel-eluting stents on
prolongation of airway bypass stent patency.
Materials and Methods
Specially bred research mongrel dogs were used for the experi-
ment. The weights of the dogs were between 20 and 25 kg. The
airway bypass procedure was performed with the animals under
Figure 1. Equipment used in procedure for airway bypass stent
placement Equipment from top to bottom: 4.9-mm flexible bron-
choscope, Doppler probe, 25-gauge retractable needle-tipped
catheter integrated with 2.5-mm balloon, stent mounted on deliv-
ery device, expanded 3  3-mm stent from side and front views,
expanded balloon of stent delivery device.general anesthesia, and each dog was mechanically ventilated via
The Journal of Thoraca single-lumen endotracheal tube. The equipment used is shown in
Figure 1. A standard 4.9-mm external diameter flexible fiberoptic
bronchoscope with a 2-mm working channel (BF-P160; Olympus
America Inc, Melville, NY) was used to visualize the airway and
to select appropriate target sites at the segmental or subsegmental
bronchial level. A Doppler catheter (Broncus Technologies Inc,
Mountain View, Calif) inserted through the bronchoscope channel
was used to scan the target site and its adjacent area to detect and
to avoid peribronchial vessels before transbronchial fenestration.
Once an appropriate site had been identified, the Doppler probe
was exchanged for a 25-gauge transbronchial retractable needle-
tipped catheter with a 2.5-mm balloon integrated into the catheter.
Transbronchial passages were formed with the 25-gauge trans-
bronchial needle and dilated with the integrated 2.5-mm balloon.
The needle-balloon catheter was withdrawn, and a balloon-ex-
pandable stent was passed through the bronchoscope channel and
visually positioned in the newly created passage. The paclitaxel-
eluting stent used is made of stainless steel (3 mm long 3 mm wide)
embedded within silicone rubber impregnated with paclitaxel (Ex-
hale Stent; Broncus Technologies). This stent expands out on
either end from its midportion (3 mm wide) to a 5.5-mm flange that
helps to secure the stent (Figure 1). Fifty control stents (no pacli-
taxel impregnation) and 107 paclitaxel-eluting stents were placed
in 25 dogs. Each paclitaxel-eluting airway bypass stent contains
approximately 400 g paclitaxel. Most of the released drug is
delivered within the first 90 days.
Animals underwent bronchoscopy at intervals to assess stent
patency. The stent was considered to be occluded if there was
tissue ingrowth that completely filled the inside channel of the
stent for at least half its length. The general health status of the
dogs was assessed by daily clinical examination and weekly com-
plete blood count, urea, and electrolyte laboratory blood tests.
Weekly follow-up was performed to a maximum of 18 weeks. The
study had animal studies ethics committee approval. All animals
received humane care in compliance with the “Guide for the Care
and Use of Laboratory Animals” (http://www.nap.edu/catalog/




Week No. % No. %
1 5/50 10% 107/107 100%
2 2/50 4% 106/107 99%








*After the 12th week of follow-up, 16 dogs were killed and the remaining
9 dogs were followed up until the 18th week, per the study protocol.5140.html).
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Eight episodes of minor and brief bleeding occurred during
transbronchial passage formation. These were treated with
dilute topical epinephrine solution and resolved without
incident. There were no pneumothoraces or deaths associ-
ated with stent placement. No delayed hemorrhages or
pneumothoraces occurred. The animals remained clinically
well through out the study period, and there were no abnor-
mal laboratory blood test results. Ninety percent of the
control stents were found to be occluded at the first week of
bronchoscopic follow-up, and the rest were occluded by the
fourth week of follow-up (Table 1). In contrast, paclitaxel-
eluting stents had a significant prolongation of stent patency
(Table 1, Figure 2). The median duration of stent patency in
the paclitaxel group was greater than 18 weeks, because
approximately two thirds of the paclitaxel-eluting stents
were still patent at the 18-week conclusion of broncho-
Figure 2. Kaplan-Meier freedom from stent closure.62 The Journal of Thoracic and Cardiovascular Surgery ● Januascopic follow-up. Examples of patent and occluded stents,
as visualized with bronchoscopy, are shown in Figure 3.
Discussion
Emphysema is anatomically defined as irreversible increase
in the size of the air spaces distal to the terminal bronchioles,
resulting from the destructive activity of neutrophil and mac-
rophage elastase.10 It is associated with a loss of lung elastic
recoil and progressive dynamic hyperinflation of the lungs.
These changes result in enlargement of the thorax, flattening of
the diaphragm, increased work of breathing, increased dys-
pnea, and reduced exercise tolerance.11 The progressive loss
of elastic recoil traps the patient in a state of hyperinflation
in which forced expiratory effort cannot reduce the residual
volume, because the force exerted to empty the lungs col-
lapses the small airways and obstructs the outflow of gas.
Progressive hyperinflation of the lungs and hyperextension
of the chest wall also diminish inspiratory capacity. To
maintain adequate minute ventilation, the respiratory rate
must increase, resulting in an increase in the work of breath-
ing and in dyspnea.12
Surgical options in the treatment of emphysema include
lung transplantation and lung volume reduction surgery.
Both treatment modalities have specific indications, and
their use is limited to selected patients. Our group embarked
on an experimental study of airway bypass with the goal of
developing a palliative treatment for patients with homoge-
neous severe emphysema who are not candidates for either
lung transplantation or lung volume reduction surgery. We
previously found that the creation of extra-anatomic bron-
chopulmonary passages in ex vivo emphysematous lungs
resulted in the improvement of forced expiratory flow and
Figure 3. Examples of patent and oc-
cluded stents visualized on bronchos-
copy. a, Stent at time of placement. b,
Occluded control stent at 1 week of
follow-up. c, Patent paclitaxel-eluting
stent at 3 weeks of follow-up. d, Patent
paclitaxel-eluting stent at 13 weeks of
follow-up.ry 2006
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tage of the extensive collateral ventilation present in em-
physematous lungs to allow additional removal of trapped
gas and further reduction of residual volume not obtainable
through the airways. The airway bypass stent was developed
as a noncollapsing structure that would prevent the collapse
and closure of these transbronchial passages. We initially
used a radiofrequency probe to create the transbronchial
passages, but we subsequently altered the technique to use
a 22-gauge needle to create the transbronchial track and a
2.5-mm dilating balloon to expand the puncture site.7 We
now use an integrated needle-balloon device, as described in
this article. This combined device has resulted in a signifi-
cant ease, simplicity, and time saving in the formation of the
transbronchial passages.
Paclitaxel has been successfully applied to the preven-
tion of coronary artery restenosis and works by inhibiting
mitosis and prevention of neointimal proliferation while
allowing healing and endothelialization.13,14 In the preven-
tion of coronary artery in-stent stenosis, paclitaxel is con-
sidered to be best delivered locally on a drug-eluting stent to
achieve therapeutic concentrations without the risk of sys-
temic toxicity. On the basis of these findings, we chose to
assess the potential effect of paclitaxel-eluting stents on
airway bypass stent patency. Our results suggest that pac-
litaxel was effective in maintaining airway bypass stent
patency. The potential clinical application of an effective
drug-eluting airway bypass stent is that it would obviate the
need for patients to undergo regular bronchoscopic topical
application of medications to maintain airway bypass stent
patency.7 Paclitaxel-eluting coronary stents have been found to
be safe and without significant adverse effects, with the local
delivery minimizing the risks of systemic toxicity. Pacli-
taxel is widely used as an effective anticancer chemothera-
peutic agent, for which purpose it has been administered
systemically at dosages in the range of 135 to 300 mg/m2
with satisfactory patient tolerance.14-16 In comparison, the
dose used in a paclitaxel-eluting coronary stent and also in
the airway bypass stent (400 g in each stent) in this study
is a small fraction of the systemic dose delivered for che-
motherapy. In our study there were no local or systemic
adverse effects seen as a result of the paclitaxel. All the
animals remained clinically well throughout the study. Re-
sults of the weekly laboratory blood tests were also normal
during the study period. Systemic absorption of paclitaxel
and monitoring of the serum level are, however, important
issues and as such require further future evaluation beyond
the scope of this study.
In summary, it was feasible and safe to perform airway
bypass stent placement in vivo. In our canine model, most
control stents became occluded within 1 week. Placement of
paclitaxel-eluting airway bypass stents, however, resulted in
a prolonged duration of stent patency.
The Journal of ThoracWe thank Patricia Toeniskoetter, Naomi Still, and Katheryn
Cook for their technical assistance in the project.
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Discussion
Dr Steven J. Mentzer (Boston, Mass). We now have three major
approaches to the endobronchial treatment of emphysema. The
first is the bronchial valve, essentially a 1-way valve designed to
induce distal atelectasis. The second is the instillation of bioactive
agents to induce distal atelectasis and scarring. These two ap-
proaches are designed to reduce lung volumes. The third approach,
presented here, is conceptually different. It relies on collateral
ventilation to bypass obstructed airways and improve expiratory
flow.
A central question regarding this third approach to endobron-
chial treatment of emphysema is collateral ventilation in human
beings. It’s interesting, Dr Choong, that you chose the dog model.
In pigs, as you may know, there is little if any collateral ventila-
tion. The lobules in a pig lung prevent collateral ventilation. In
dogs, there are essentially no fibrous septa, and the lung is basi-
cally unlobulated. In human beings, the situation is somewhere in
ic and Cardiovascular Surgery ● Volume 131, Number 1 63
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on the dog model?
Dr. Choong. The purpose of this study was to assess the
patency of paclitaxel-eluting airway bypass stents in a dog model.
As previously mentioned, the dogs used in the study were normal
dogs with normal lungs. We have previously provided the defini-
tion of an occluded stent as one with tissue ingrowth occupying
half or more of the stent channel. The patency of the stents was
therefore assessed in accordance with that definition. The purpose
of this study was not to assess the effects of airway bypass stents
on collateral ventilation. These normal dogs had normal lungs and
therefore did not have significant collateral ventilation. Collateral
ventilation is present in human beings and is especially significant
in patients with emphysematous lungs. We believe that the airway
bypass stents would take advantage of that situation and improve
expiratory flow and volume in patients with emphysema. We have
done experimental studies with explanted emphysematous human
lungs obtained from lung transplant recipients during lung trans-
plantations, with patient and ethics committee approval, and these
studies demonstrated that airway bypass stents do take advantage
of the significant collateral ventilation that is present in emphyse-
matous lungs, leading to improvement in expiratory flow and
volume and reduction in hyperinflation. Preliminary clinical stud-
ies in human patients have also confirmed these results.
Dr Mentzer. However, one would imagine that if you have
collateral ventilation, the chance of having continuous ventilation
and a patent stent would improve. Conversely, if you have distal
atelectasis, the amount of ventilation distal to the stent would be
diminished.
A related point regards the time constant of the stents. If the
amount of time that it takes for air flow to go across the stent is
relatively large relative to the ventilatory cycle, then the contribu-
tion of those stents to overall ventilatory function would be small.
Clearly, the time constant is dependent on stent patency. As these
stents start to occlude, you would expect the time constant to go up
and the relative benefit of the stent to go down.
Dr Choong. Exactly. I think one of the critical issues for this
to be successful is to ensure that the stents stay patent.
Dr Mentzer. It seems logical that if the stents are truly decom-
pressing distal emphysematous lung, you might affect distal hy-
perinflation. For example, dynamic hyperinflation might be less
and air flow improved with these additional air passages. Do you
have any evidence, in animals or in human beings, that dynamic
hyperinflation is in fact improved with stent therapy?
Dr Choong. We are currently conducting experimental studies
specifically looking at this area, together with Drs Peter Macklem,
John Pierce, and Jim Hogg. In our studies, the airway bypass stents
resulted in improvement in the physiologic and mechanical prop-
erties of explanted emphysematous human lungs. Preliminary clin-
ical studies in human patients have confirmed these results.
64 The Journal of Thoracic and Cardiovascular Surgery ● JanuaDr Mentzer. Mechanical ventilation improved, but did you get
improvement in blood gases? It seems plausible that you could
simply be improving ventilation to dead space; that is, you may be
increasing the overall air flow, but perhaps only by increasing your
dead space ventilation.
Dr Choong. In terms of looking at the blood gas values, we
have not done this in the experimental or clinical studies that we’re
conducting. In our experimental and clinical studies, however, the
airway bypass stents did result in a decrease in the trapped gas and
the residual volumes of emphysematous lungs.
Dr Joseph B. Shrager (Philadelphia, Pa). This was a nice
presentation of obviously exciting work. I’m particularly excited to
see the picture you presented from the human lung, which is the
first one I’ve seen where you can actually visualize the lung
parenchyma directly through the hole; on the other hand, in the
pictures that you showed in the animals, at least the ones you
presented here today, it’s not entirely clear to me that you can tell
objectively whether the stent is open. Is it a “plus/minus” obvious
event whether the thing is open?
Dr Choong. Yes. The picture I showed of the airway bypass
stent that was placed in a patient with severe emphysema shows
clearly the appearance of a patent stent and the markedly destroyed
emphysematous lung seen through the stent channel.
Dr Shrager. Isn’t there a degree of subjective interpretation as
to whether a stent has remained open? If it is a little bit subjective,
is there something else you can do to make sure they are in fact
open? Are there any adjunctive things that you are doing broncho-
scopically to tell whether they are really open?
Dr Choong. In the animal studies that we conducted, we used
normal research mongrel dogs with normal lung tissues. They did
not have emphysematous lungs. Therefore, in the pictures I have
shown, you’re looking at solid lung parenchyma at the other end of
the stent channel. The way we define stent occlusion is that half or
more of the stent channel is occupied by tissue. You are right that
in emphysematous human lungs there is a definite, clear view of
the destroyed lung tissue; unfortunately, we do not have this
situation in the normal research mongrel dogs with normal lungs.
Dr Shrager. So you are not really sure whether there is air
flowing back and forth through these stents that you’re calling
open?
Dr Choong. There is most likely no air flow in these normal
lungs, but the purpose of this study was to look at the patency
according to the definition previously described. We have, how-
ever, used the paclitaxel-eluting airway bypass stents in human
clinical studies, and we have found encouraging results with these
stents being patent and looking that way during follow-up.
Dr Shrager. For how long do they elute paclitaxel?
Dr Choong. Most of the elution occurs though a 3-monthperiod.
ry 2006
